Descrição
🎥 Video Details 🎥
🌟 About This Video 🌟
Eli Lilly announced Monday it will acquire Kelonia Therapeutics for $3.25 billion upfront to expand its oncology and genetic medicines pipeline. The acquisition centers on in vivo CAR-T technology and KLN-1010, an investigational one-time intravenous gene therapy designed to generate anti-BCMA CAR-T cells for multiple myeloma. Early Phase 1 results were presented at the 2025 ASH Annual Meeting.
Lilly said Kelonia’s iGPS platform enables in vivo gene placement using engineered lentiviral particles, avoiding autologous manufacturing. The deal is expected to close in the second half of 2026, pending regulatory approvals. Earlier this year, Lilly agreed to acquire Orna Therapeutics and partnered with Nvidia to advance AI-driven drug discovery. #biotechacquisition #genetherapy #cancertreatment #elililly
🤖 Crafted with Rizzle AI 🤖
This video was created using Rizzle AI, the ingenious no-edit video creation platform, with industry-leading assets from GettyImages and Soundstripe. Elevate your video content with Rizzle AI: https://app.rizzle.com/create
🔔 If you enjoyed this video, don't forget to like, share, and subscribe! 🔔